+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Central Nervous System Biomarkers Market Research Report by Disease Indication, Application, End-User, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

  • PDF Icon

    Report

  • 245 Pages
  • January 2023
  • Region: Global
  • 360iResearch™
  • ID: 5715500
UP TO OFF until Mar 31st 2023
The Global Central Nervous System Biomarkers Market size was estimated at USD 3,981.24 million in 2022, USD 4,374.18 million in 2023, and is projected to grow at a CAGR of 10.32% to reach USD 8,738.77 million by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Central Nervous System Biomarkers Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Central Nervous System Biomarkers Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Central Nervous System Biomarkers Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Central Nervous System Biomarkers Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Central Nervous System Biomarkers Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Disease Indication, the market is studied across Alzheimer’s Disease, Multiple Sclerosis, Parkinson’s Disease, and Traumatic Brain Injury.
  • Based on Application, the market is studied across Diagnostics, Disease Risk Assessment, Drug Discovery & Development, and Personalized Medicines.
  • Based on End-User, the market is studied across Clinics & Hospitals, Diagnostic Labs, and Research Centers.
  • Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Central Nervous System Biomarkers Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Central Nervous System Biomarkers Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Central Nervous System Biomarkers Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Central Nervous System Biomarkers Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Central Nervous System Biomarkers Market, including Abbott Laboratories, Acumen Pharmaceuticals Inc., Aposense, Applied NeuroSolutions, Inc., DiaGenic ASA, F. Hoffmann-La Roche AG, Geno Technology Inc., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Quanterix Corporation, Siemens Healthcare GmbH, SynapCell, and Thermo Fisher Scientific Inc..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Central Nervous System Biomarkers Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Central Nervous System Biomarkers Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Central Nervous System Biomarkers Market?
4. What is the competitive strategic window for opportunities in the Global Central Nervous System Biomarkers Market?
5. What are the technology trends and regulatory frameworks in the Global Central Nervous System Biomarkers Market?
6. What is the market share of the leading vendors in the Global Central Nervous System Biomarkers Market?
7. What modes and strategic moves are considered suitable for entering the Global Central Nervous System Biomarkers Market?
Frequently Asked Questions about the Global Central Nervous System Biomarkers Market

What is the estimated value of the Global Central Nervous System Biomarkers Market?

The Global Central Nervous System Biomarkers Market was estimated to be valued at $3981.24 Million in 2022.

What is the growth rate of the Global Central Nervous System Biomarkers Market?

The growth rate of the Global Central Nervous System Biomarkers Market is 10.3%, with an estimated value of $8738.77 Million by 2030.

What is the forecasted size of the Global Central Nervous System Biomarkers Market?

The Global Central Nervous System Biomarkers Market is estimated to be worth $8738.77 Million by 2030.

Who are the key companies in the Global Central Nervous System Biomarkers Market?

Key companies in the Global Central Nervous System Biomarkers Market include Abbott Laboratories, Acumen Pharmaceuticals Inc., Aposense, Applied NeuroSolutions, Inc., DiaGenic ASA, F. Hoffmann, La Roche AG, Geno Technology Inc. and Merck & Co., Inc..

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increase in obesity leading to neurological illnesses
5.1.1.2. Availability of central nervous system biomarkers for clinical use
5.1.1.3. Development of genomics, proteomics, and imaging systems
5.1.2. Restraints
5.1.2.1. High validation cost and unfavorable reimbursement costs
5.1.3. Opportunities
5.1.3.1. Improving research and development activities for central nervous system biomarkers
5.1.3.2. Emerging focus on building strategic alliances and introduction of new products and technology
5.1.4. Challenges
5.1.4.1. Lack of skilled technical professionals
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Central Nervous System Biomarkers Market, by Disease Indication
6.1. Introduction
6.2. Alzheimer’s Disease
6.3. Multiple Sclerosis
6.4. Parkinson’s Disease
6.5. Traumatic Brain Injury

7. Central Nervous System Biomarkers Market, by Application
7.1. Introduction
7.2. Diagnostics
7.3. Disease Risk Assessment
7.4. Drug Discovery & Development
7.5. Personalized Medicines

8. Central Nervous System Biomarkers Market, by End-User
8.1. Introduction
8.2. Clinics & Hospitals
8.3. Diagnostic Labs
8.4. Research Centers

9. Americas Central Nervous System Biomarkers Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Central Nervous System Biomarkers Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Central Nervous System Biomarkers Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Product Portfolio Analysis, By Key Player
12.5. Competitive Scenario
12.5.1. Merger & Acquisition
12.5.2. Agreement, Collaboration, & Partnership
12.5.3. New Product Launch & Enhancement
12.5.4. Investment & Funding
12.5.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Abbott Laboratories
13.2. Acumen Pharmaceuticals Inc.
13.3. Aposense
13.4. Applied NeuroSolutions, Inc.
13.5. DiaGenic ASA
13.6. F. Hoffmann-La Roche AG
13.7. Geno Technology Inc.
13.8. Laboratory Corporation of America Holdings
13.9. Merck & Co., Inc.
13.10. Myriad Genetics, Inc.
13.11. Novartis AG
13.12. Quanterix Corporation
13.13. Siemens Healthcare GmbH
13.14. SynapCell
13.15. Thermo Fisher Scientific Inc.

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing


List of Figures
FIGURE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET DYNAMICS
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2030 (%)
FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY DISEASE INDICATION, 2030
FIGURE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2030 (USD MILLION)
FIGURE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
FIGURE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2030 (USD MILLION)
FIGURE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2030 (USD MILLION)
FIGURE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)
FIGURE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY APPLICATION, 2030
FIGURE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
FIGURE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, 2018-2030 (USD MILLION)
FIGURE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
FIGURE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, 2018-2030 (USD MILLION)
FIGURE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2030 (%)
FIGURE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY END-USER, 2030
FIGURE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, 2018-2030 (USD MILLION)
FIGURE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
FIGURE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
FIGURE 32. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 33. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 34. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 35. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 36. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 37. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 38. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 39. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 40. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 41. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 42. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 43. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 44. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 45. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 46. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 47. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 48. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 49. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 50. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 51. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 52. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 53. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 54. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 55. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 56. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 57. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 58. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 59. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 60. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 61. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 62. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 63. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 64. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 65. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 66. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 67. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 68. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 69. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 70. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 71. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 72. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 73. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 74. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 75. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 76. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 77. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 78. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 79. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 80. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 81. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 82. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 83. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 84. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 85. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 86. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 87. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022


List of Tables
TABLE 1. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY CLINICS & HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSTIC LABS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 48. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 49. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 52. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 53. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 55. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 56. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 59. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 60. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 61. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 77. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 78. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 79. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. CHINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 82. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 83. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 84. INDIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 88. INDONESIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 89. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 90. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 91. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. JAPAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 114. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 115. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 116. THAILAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 117. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 126. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 127. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 128. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 129. DENMARK CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 131. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 132. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. EGYPT CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 134. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 135. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 136. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 137. FINLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 138. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 139. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 140. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 141. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 143. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 144. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 145. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 146. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 147. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 148. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 149. ISRAEL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 151. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 152. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 153. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 158. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 159. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 160. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 161. NIGERIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 162. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 163. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 164. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 165. NORWAY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 167. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 168. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 169. POLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 170. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 171. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 172. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. QATAR CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 175. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 176. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 179. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 180. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. SAUDI ARABIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 184. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 185. SOUTH AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 187. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 188. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 189. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 191. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 192. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 193. SWEDEN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 195. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 196. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 197. SWITZERLAND CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 199. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 201. TURKEY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 206. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 207. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
TABLE 208. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 209. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 211. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 212. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 213. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 214. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 215. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 216. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET MERGER & ACQUISITION
TABLE 217. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 218. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 219. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET INVESTMENT & FUNDING
TABLE 220. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 221. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: LICENSE & PRICING

Companies Mentioned

  • Abbott Laboratories
  • Acumen Pharmaceuticals Inc.
  • Aposense
  • Applied NeuroSolutions, Inc.
  • DiaGenic ASA
  • F. Hoffmann-La Roche AG
  • Geno Technology Inc.
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Quanterix Corporation
  • Siemens Healthcare GmbH
  • SynapCell
  • Thermo Fisher Scientific Inc.

Methodology

Loading
LOADING...